CD4 and T-cell immunodeficiency: This patient showed evidence of T-cell immunodeficiency (<100 cells/μL) before initiation of BsAb that worsened and persisted following BsAb treatment with a CD4 T-cell count <50 cells/μL more than 1 year after cessation of BsAb therapy, highlighting the potential impact of T-cell exhaustion after long-term BsAb with consequences including OIs [13].